Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KPTI Karyopharm Therapeutics	$4.55 -0.9%	$5.13	$3.51 ▼ $17.40	$39.31M	0.33	82,104 shs	99,040 shs
NAMS NewAmsterdam Pharma	$17.01 -3.4%	$18.32	$14.06 ▼ $27.29	$1.87B	0.01	639,792 shs	807,213 shs
NGM NGM Biopharmaceuticals	$1.54	$1.55	$0.60 ▼ $4.69	$128.53M	1.27	1.47 million shs	N/A
XOMA XOMA	$24.92 +0.3%	$22.67	$18.35 ▼ $35.00	$298.22M	0.89	30,822 shs	21,233 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KPTI Karyopharm Therapeutics	-0.87%	-11.82%	-19.04%	-53.71%	-71.11%
NAMS NewAmsterdam Pharma	-3.41%	-12.09%	-2.91%	-13.70%	-9.62%
NGM NGM Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
XOMA XOMA	+0.28%	-6.32%	+3.23%	+8.68%	+0.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KPTI Karyopharm Therapeutics	3.9502 of 5 stars	3.5	0.0	0.0	4.6	3.6	2.5	0.6
NAMS NewAmsterdam Pharma	2.5779 of 5 stars	3.5	1.0	0.0	0.0	2.8	5.0	0.0
NGM NGM Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	4.0922 of 5 stars	3.5	2.0	0.0	3.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	849.45% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	152.79% Upside
NGM NGM Biopharmaceuticals	0.00	N/A	N/A	N/A
XOMA XOMA	3.00	Buy	$69.50	178.89% Upside

Current Analyst Ratings Breakdown

Latest KPTI, NGM, NAMS, and XOMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
4/17/2025	XOMA XOMA	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/28/2025	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00 ➝ $104.00
3/19/2025	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00 ➝ $104.00
3/3/2025	NAMS NewAmsterdam Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$41.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KPTI Karyopharm Therapeutics	$142.13M	0.28	N/A	N/A	($1.47) per share	-3.10
NAMS NewAmsterdam Pharma	$47.14M	39.63	N/A	N/A	$3.50 per share	4.86
NGM NGM Biopharmaceuticals	$4.42M	29.10	N/A	N/A	$1.80 per share	0.86
XOMA XOMA	$13.05M	22.86	N/A	N/A	$7.72 per share	3.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
NGM NGM Biopharmaceuticals	-$142.38M	-$1.72	N/A	N/A	N/A	-3,223.34%	-77.85%	-67.76%	N/A
XOMA XOMA	-$40.83M	-$1.15	N/A	N/A	N/A	-151.34%	-24.95%	-9.64%	8/12/2025 (Estimated)

Latest KPTI, NGM, NAMS, and XOMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	XOMA XOMA	-$0.26	$0.06	+$0.32	$0.06	$6.75 million	$15.91 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
3/17/2025	Q4 2024	XOMA XOMA	-$0.29	-$0.46	-$0.17	-$0.46	$8.75 million	$8.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
NGM NGM Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
NGM NGM Biopharmaceuticals	N/A	7.79	7.79
XOMA XOMA	1.28	7.52	7.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KPTI Karyopharm Therapeutics	66.44%
NAMS NewAmsterdam Pharma	89.89%
NGM NGM Biopharmaceuticals	75.74%
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
KPTI Karyopharm Therapeutics	2.75%
NAMS NewAmsterdam Pharma	20.84%
NGM NGM Biopharmaceuticals	35.90%
XOMA XOMA	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
NAMS NewAmsterdam Pharma	4	109.82 million	74.37 million	Optionable
NGM NGM Biopharmaceuticals	138	83.46 million	53.50 million	Optionable
XOMA XOMA	10	11.97 million	10.94 million	Optionable

KPTI, NGM, NAMS, and XOMA Headlines

Recent News About These Companies

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

May 27 at 8:01 AM | globenewswire.com

Woodline Partners LP Acquires 60,927 Shares of XOMA Co. (NASDAQ:XOMA)

May 27 at 4:37 AM | marketbeat.com

Insider Selling: XOMA Co. (NASDAQ:XOMA) CEO Sells 25,637 Shares of Stock

May 22, 2025 | insidertrades.com

Bvf Partners L. P/Il Sells 392,723 Shares of XOMA Co. (NASDAQ:XOMA) Stock

May 21, 2025 | insidertrades.com

Major Shareholder Sells Massive Chunk of Xoma Stock!

May 20, 2025 | tipranks.com

Stonepine Capital Management LLC Reduces Stock Holdings in XOMA Co. (NASDAQ:XOMA)

May 20, 2025 | marketbeat.com

Leerink Partnrs Analysts Boost Earnings Estimates for XOMA

May 20, 2025 | marketbeat.com

XOMA Royalty First Quarter 2025 Earnings: Beats Expectations

May 15, 2025 | finance.yahoo.com

XOMA Royalty Reports Strong Q1 2025 Results

May 14, 2025 | tipranks.com

XOMA Royalty: Q1 Earnings Snapshot

May 13, 2025 | sfgate.com

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

May 13, 2025 | finance.yahoo.com

XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates

May 13, 2025 | zacks.com

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 7, 2025 | globenewswire.com

XOMA (XOMA) Expected to Announce Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

High Growth Tech Stocks In The US To Watch April 2025

April 22, 2025 | uk.finance.yahoo.com

Benchmark Initiates Coverage of XOMA Royalty Corporation - Preferred Stock (XOMAP) with Buy Recommendation

April 18, 2025 | msn.com

Xoma initiated with a Buy at Benchmark

April 17, 2025 | markets.businessinsider.com

Xoma (XOMA) Receives Buy Rating from Benchmark with Promising Growth Forecast | XOMA Stock News

April 17, 2025 | gurufocus.com

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

April 14, 2025 | gurufocus.com

XOMA (XOMA) Sells Kinnate Biopharma Pipeline Assets for Potential $270M | XOMA Stock News

April 14, 2025 | gurufocus.com

XOMA Royalty Completes Sale of Kinnate Pipeline Assets | XOMA Stock News

April 14, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, NGM, NAMS, and XOMA Company Descriptions

Karyopharm Therapeutics NASDAQ:KPTI

$4.55 -0.04 (-0.87%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$4.59 +0.04 (+0.88%)

As of 05/27/2025 04:04 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$17.01 -0.60 (-3.41%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$17.01 0.00 (0.00%)

As of 05/27/2025 06:01 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NGM Biopharmaceuticals NASDAQ:NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

XOMA NASDAQ:XOMA

$24.92 +0.07 (+0.28%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$24.95 +0.03 (+0.12%)

As of 05/27/2025 04:04 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time